tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Heart Failure D006333 36 associated lipids
Angioedema D000799 6 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Trypanosomiasis D014352 5 associated lipids
Alopecia D000505 14 associated lipids
Liver Diseases D008107 31 associated lipids
Corneal Diseases D003316 13 associated lipids
Testicular Diseases D013733 15 associated lipids
Facial Dermatoses D005148 7 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Infection D007239 6 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Bone Diseases D001847 4 associated lipids
Leukemia P388 D007941 43 associated lipids
Ulcer D014456 16 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Obesity D009765 29 associated lipids
Thrombosis D013927 49 associated lipids
Bradycardia D001919 13 associated lipids
Hemorrhage D006470 15 associated lipids
Proteinuria D011507 30 associated lipids
Lymphoma D008223 18 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Alzheimer Disease D000544 76 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Eye Diseases D005128 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Morello RJ et al. Remote ischemic preconditioning and tacrolimus in the fetal small bowel transplant in mice. 2016 Acta Cir Bras pmid:27828601
Lee SG et al. Enhanced topical delivery of tacrolimus by a carbomer hydrogel formulation with transcutol P. 2016 Drug Dev Ind Pharm pmid:26925849
Koura-Nishiura A et al. Clearance of atypical facial necrobiosis lipoidica with tacrolimus ointment. 2016 J Eur Acad Dermatol Venereol pmid:25353715
Lee SH et al. Low-dose mycophenolate mofetil in tablet form or capsule form combined with tacrolimus in the early period after kidney transplantation: a prospective randomized trial
. 2016 Clin. Nephrol. pmid:27781419
Cortes M et al. The use of temporary portocaval shunt as a technical aid in auxiliary orthotopic liver transplantation. 2016 Liver Transpl. pmid:27357622
Nascimento J and Machado S Pediatric-onset necrobiosis lipoidica. 2016 Pediatr Int pmid:26865027
Ueno KI et al. Advantage of administering tacrolimus for improving prognosis of patients with polymyositis and dermatomyositis. 2016 Int J Rheum Dis pmid:27457756
Barreto P et al. Conversion From Twice-Daily to Once-Daily Tacrolimus in Stable Kidney Graft Recipients. 2016 Transplant. Proc. pmid:27742278
Robinson CL et al. Posaconazole in lung transplant recipients: use, tolerability, and efficacy. 2016 Transpl Infect Dis pmid:26781986
Rodríguez-Lago I et al. Previous exposure to biologics and C-reactive protein are associated with the response to tacrolimus in inflammatory bowel disease. 2016 Rev Esp Enferm Dig pmid:27604685
Pereira M et al. Hyperacute Rejection in a Kidney Transplant With Negative Crossmatch: A Case Report. 2016 Transplant. Proc. pmid:27742303
Rostaing L et al. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. 2016 Am. J. Kidney Dis. pmid:26717860
Shuker N et al. A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation. 2016 Am. J. Transplant. pmid:26714287
Spain L et al. Management of toxicities of immune checkpoint inhibitors. 2016 Cancer Treat. Rev. pmid:26874776
Juvvadi PR et al. Novel motif in calcineurin catalytic subunit is required for septal localization of calcineurin in Aspergillus fumigatus. 2016 FEBS Lett. pmid:26864964
Solomon A Allergic manifestations of contact lens wearing. 2016 Curr Opin Allergy Clin Immunol pmid:27518840
Navarro-Villarán E et al. Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies. 2016 PLoS ONE pmid:27518575
Jung HJ et al. Improved oral absorption of tacrolimus by a solid dispersion with hypromellose and sodium lauryl sulfate. 2016 Int. J. Biol. Macromol. pmid:26642839
Hirsch HH et al. BK Polyomavirus Replication in Renal Tubular Epithelial Cells Is Inhibited by Sirolimus, but Activated by Tacrolimus Through a Pathway Involving FKBP-12. 2016 Am. J. Transplant. pmid:26639422
Cassuto E et al. Adherence to and Acceptance of Once-Daily Tacrolimus After Kidney and Liver Transplant: Results From OSIRIS, a French Observational Study. 2016 Transplantation pmid:27653227
Saliba F et al. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study. 2016 Transplantation pmid:27454919
Butts AR et al. Factors associated with optimized tacrolimus dosing in hematopoietic stem cell transplantation. 2016 J Oncol Pharm Pract pmid:25802301
Zhao CY et al. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. 2016 Br J Clin Pharmacol pmid:26574188
Zhang X et al. The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis. 2016 Int Urol Nephrol pmid:26781720
Vadcharavivad S et al. Validation of a 2-Point Limited Sampling Strategy to Predict the Tacrolimus Area-Under-the-12-Hour-Curve in Kidney Transplant Recipients. 2016 Ther Drug Monit pmid:27328329
Luo X et al. Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5(*)3 genotype in Chinese renal transplant recipients. 2016 Acta Pharmacol. Sin. pmid:26924289
Raja R et al. A prospective study of collapsing focal segmental glomerulosclerosis. 2016 Ren Fail pmid:27266801
De Meyer M et al. Pharmacogenetic-based strategy using de novo tacrolimus once daily after kidney transplantation: prospective pilot study. 2016 Pharmacogenomics pmid:27266721
Wilkes SR et al. How Clinically Relevant Are Treatment Comparisons of Topical Calcineurin Inhibitor Trials for Atopic Eczema? 2016 J. Invest. Dermatol. pmid:27265005
Bagherani N Comparison of pimecrolimus with clobetasol propionate in the treatment of localized vitiligo. 2016 Dermatol Ther pmid:26445411
Gaynor JJ et al. Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation. 2016 Transpl. Int. pmid:26442829
Ha DH et al. Effects of tacrolimus on morphology, proliferation and differentiation of mesenchymal stem cells derived from gingiva tissue. 2016 Mol Med Rep pmid:27177273
Jin J et al. Klotho Deficiency Aggravates Tacrolimus-Induced Renal Injury via the Phosphatidylinositol 3-Kinase-Akt-Forkhead Box Protein O Pathway. 2016 Am. J. Nephrol. pmid:27174564
Bruns K et al. Quantitative determination of four immunosuppressants by high resolution mass spectrometry (HRMS). 2016 Clin. Chem. Lab. Med. pmid:26641969
Zamorano-Leon JJ et al. New strategy of tacrolimus administration in animal model based on tacrolimus-loaded microspheres. 2016 Transpl. Immunol. pmid:27102446
Dasgupta A et al. Analytical Performance Evaluation of a New Cobas Tacrolimus Assay on Cobas e411 Analyzer: Comparison of Values Obtained by the CMIA Tacrolimus Assay and a Liquid Chromatography Combined with Tandem Mass Spectrometric Method. 2016 Ann. Clin. Lab. Sci. pmid:27098629
Watanabe H et al. The efficacy of add-on tacrolimus for minor flare in patients with systemic lupus erythematosus: a retrospective study. 2016 Lupus pmid:26296361
Tang JT et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. 2016 Expert Opin Drug Metab Toxicol pmid:27010623
Wakamatsu A et al. Role of calcineurin (CN) in kidney glomerular podocyte: CN inhibitor ameliorated proteinuria by inhibiting the redistribution of CN at the slit diaphragm. 2016 Physiol Rep pmid:27009276
Rivelli RF et al. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant. 2015 Nephrology (Carlton) pmid:25404086
Birdwell KA et al. Assessment of arterial stiffness using pulse wave velocity in tacrolimus users the first year post kidney transplantation: a prospective cohort study. 2015 BMC Nephrol pmid:26133166
Cury Martins J et al. Topical tacrolimus for atopic dermatitis. 2015 Cochrane Database Syst Rev pmid:26132597
Prinz V et al. MRI heralds secondary nigral lesion after brain ischemia in mice: a secondary time window for neuroprotection. 2015 J. Cereb. Blood Flow Metab. pmid:26126863
Gordon P and Gooptu B Tacrolimus in idiopathic inflammatory myopathy-associated interstitial lung disease: defining roles and responders. 2015 Rheumatology (Oxford) pmid:25342374
Milam EC et al. Treatment of Scarring Alopecia in Discoid Variant of Chronic Cutaneous Lupus Erythematosus With Tacrolimus Lotion, 0.3. 2015 JAMA Dermatol pmid:26039539
Shi WL et al. Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis. 2015 PLoS ONE pmid:26039043
Argudo A et al. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation. 2015 Transplant. Proc. pmid:26518936
Söderlund C and Rådegran G Safety and efficacy of the switch to generic mycophenolate mofetil and tacrolimus in heart transplant patients. 2015 Clin Transplant pmid:25981927
van Boekel GA et al. Limited sampling strategy for prolonged-release tacrolimus in renal transplant patients by use of the dried blood spot technique. 2015 Eur. J. Clin. Pharmacol. pmid:25980838
de Jonge H et al. The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. 2015 Pharmacogenomics J. pmid:25287072
Jin S et al. Exposure to Radiocontrast Agents Induces Pancreatic Inflammation by Activation of Nuclear Factor-κB, Calcium Signaling, and Calcineurin. 2015 Gastroenterology pmid:25980752
Wiseman AC Induction Therapy in Renal Transplantation: Why? What Agent? What Dose? We May Never Know. 2015 Clin J Am Soc Nephrol pmid:25979977
Ratanatharathorn V et al. Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. 2015 Bone Marrow Transplant. pmid:25285804
Kang YZ et al. Autoimmune hepatitis-primary biliary cirrhosis concurrent with biliary stricture after liver transplantation. 2015 World J. Gastroenterol. pmid:25717264
Murata M Prophylactic and therapeutic treatment of graft-versus-host disease in Japan. 2015 Int. J. Hematol. pmid:25864188
Hategan A and Bourgeois JA Tacrolimus neurotoxicity and the role of the Renin-Angiotensin system. 2015 J Neuropsychiatry Clin Neurosci pmid:25923858
Blasco-Morente G et al. Long-Standing Presternal Plaque. 2015 Actas Dermosifiliogr pmid:25917959
Ferraresso M et al. Relationship between mRNA expression levels of CYP3A4, CYP3A5 and SXR in peripheral mononuclear blood cells and aging in young kidney transplant recipients under tacrolimus treatment. 2015 Pharmacogenomics pmid:25916520
Li JS et al. Angiopoietin-Like-4, a Potential Target of Tacrolimus, Predicts Earlier Podocyte Injury in Minimal Change Disease. 2015 PLoS ONE pmid:26352670
Lin S et al. Interleukin-2 receptor antagonist therapy leads to increased tacrolimus levels after kidney transplantation. 2015 Ther Drug Monit pmid:25162212
Josephson MA et al. American society of Nephrology Quiz and Questionnaire 2014: transplantation. 2015 Clin J Am Soc Nephrol pmid:25862775
Peña C et al. [Secondary acute myeloid leukemia in a lung allograft recipient. Report of one case]. 2015 Rev Med Chil pmid:25860370
Liu S et al. Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study. 2015 BMC Nephrol pmid:26637482
Watanabe K et al. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease. 2015 Mol Brain pmid:26637371
Wang L et al. Effect of CYP3A5 gene polymorphisms on tacrolimus concentration/dosage ratio in adult liver transplant patients. 2015 Genet. Mol. Res. pmid:26634478
Solomon SR et al. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. 2015 Biol. Blood Marrow Transplant. pmid:25797174
Dedinská I et al. Waist circumference as an independent risk factor for NODAT. 2015 Ann. Transplant. pmid:25791039
Furie R et al. Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis. 2015 Semin. Nephrol. pmid:26573553
Abe Y et al. Successful Management of Lupus Nephritis with High Titers of Myeloperoxidase Anti-Neutrophil Cytoplasmic Antibodies Using Tacrolimus. 2015 Intern. Med. pmid:26568012
William BM and de Lima M Sirolimus plus calcineurin inhibitors and methotrexate: is more necessarily better? 2015 Leuk. Lymphoma pmid:25065702
Gu L et al. A retrospective study to compare the use of tacrolimus and cyclosporine in combination with adriamycin in post-transplant liver cancer patients. 2015 Cell Biochem. Biophys. pmid:25287673
Ambrosioni J et al. Role of rhinovirus load in the upper respiratory tract and severity of symptoms in lung transplant recipients. 2015 J. Clin. Virol. pmid:25728070
Marcus EA et al. Successful term pregnancy in an intestine-pancreas transplant recipient with chronic graft dysfunction and parenteral nutrition dependence: a case report. 2015 Transplant. Proc. pmid:25724255
Dias PH et al. Effects of immunosuppression with tacrolimus and mycophenolate mofetil on renal histology and function in single kidney rats submitted to ischemia and reperfusion. 2015 Acta Cir Bras pmid:25714692
Townamchai N et al. A Simple Novel Technique to Estimate Tacrolimus Dosages During the Early Post Kidney Transplantation Period. 2015 Transplant. Proc. pmid:26518946
San Miguel C et al. Immunosuppression Strategies in the Treatment of Hepatocellular Carcinoma in Virgen de las Nieves University Hospital. 2015 Transplant. Proc. pmid:26518930
Kadlub N et al. The calcineurin inhibitor tacrolimus as a new therapy in severe cherubism. 2015 J. Bone Miner. Res. pmid:25491283
Katayama K et al. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice. 2015 Mod Rheumatol pmid:24983407
Tavira B et al. The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients. 2015 J. Hum. Genet. pmid:25673014
Wang Y et al. Justification of noninferiority margin: methodology considerations in an exposure-response analysis. 2015 Clin. Pharmacol. Ther. pmid:25670256
Dumortier T et al. Estimating the contribution of everolimus to immunosuppressive efficacy when combined with tacrolimus in liver transplantation: a model-based approach. 2015 Clin. Pharmacol. Ther. pmid:25669933
Kikuchi T et al. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. 2015 Int. J. Hematol. pmid:26440970
Dai DS et al. Protective Effect of Salvia Przewalskii Extract on Puromycin-Induced Podocyte Injury. 2015 Am. J. Nephrol. pmid:26439819
Xie X et al. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis. 2015 BMC Nephrol pmid:26126806
Aouam K et al. Development of Limited Sampling Strategies for the Estimation of Tacrolimus Area Under the Curve in Adult Kidney Transplant Recipients According to the Posttransplantation Time. 2015 Ther Drug Monit pmid:25627405
Oguni H and Hayashi M [Topics for authorization of new intravenous antiepileptic drugs and tacrolimus for autoimmune epilepsy]. 2015 No To Hattatsu pmid:26349372
Dave CN et al. Innovative use of intravesical tacrolimus for hemorrhagic radiation cystitis. 2015 Int Urol Nephrol pmid:26347076
Wu J et al. MicroRNA-30 family members regulate calcium/calcineurin signaling in podocytes. 2015 J. Clin. Invest. pmid:26436650
Bhadauria D et al. Cryptosporidium infection after renal transplantation in an endemic area. 2015 Transpl Infect Dis pmid:25620388
Luger T et al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. 2015 Pediatr Allergy Immunol pmid:25557211
Burke MT et al. Genetics and nonmelanoma skin cancer in kidney transplant recipients. 2015 Pharmacogenomics pmid:25616102
Schnitzler F et al. Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort. 2015 PLoS ONE pmid:26288187
Al-Harbi NO et al. Treatment with aliskiren ameliorates tacrolimus-induced nephrotoxicity in rats. 2015 J Renin Angiotensin Aldosterone Syst pmid:24737642
Lawrence MC et al. NFAT targets signaling molecules to gene promoters in pancreatic β-cells. 2015 Mol. Endocrinol. pmid:25496032
Chakraborty S et al. Prediction of in vivo drug performance using in vitro dissolution coupled with STELLA: a study with selected drug products. 2015 Drug Dev Ind Pharm pmid:25494535
Scholz FM et al. Focal metatarsal fistulae syndrome affecting a greyhound dog successfully treated with topical 0.1% tacrolimus ointment. 2015 Vet. Dermatol. pmid:26216245
Hauch A et al. Generics: are all immunosuppression agents created equally? 2015 Surgery pmid:26206317
Borda B et al. [Frequency of T-cell mediated rejection in new-onset diabetes after kidney transplantation]. 2015 Orv Hetil pmid:26039918
Albring A et al. Relationship between pharmacokinetics and pharmacodynamics of calcineurin inhibitors in renal transplant patients. 2015 Clin Transplant pmid:25557538
Türkoğlu O et al. Are antimicrobial peptides related to cyclosporine A-induced gingival overgrowth? 2015 Arch. Oral Biol. pmid:25555253